Cationic lipid nanosystems as carriers for nucleic acids

New Biotechnology

Volumn 31, Issue 1, 2014, Pages 44-54

  Cortesi, Rita ^a   Campioni, Matteo ^a   Ravani, Laura ^a   Drechsler, Markus ^b   Pinotti, Mirko ^a   Esposito, Elisabetta ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CHLORIDE; AQUEOUS DISPERSIONS; CHARGE PROPERTIES; ELECTROSTATIC COMPLEXES; EXPERIMENTAL PROTOCOLS; FIREFLY LUCIFERASE; GREEN FLUORESCENT PROTEIN; SOLID LIPID NANOPARTICLES;

BIOMOLECULES; CATIONIC SURFACTANTS; CHLORINE COMPOUNDS; CYTOTOXICITY; DYES; ELECTROPHORESIS; NUCLEIC ACIDS;

NANOSYSTEMS;

AGAROSE; DIISOBUTYLPHENOXYETHYL DIMETHYLBENZYL AMMONIUM CHLORIDE; DNA; FIREFLY LUCIFERASE; GLYCEROL OLEATE; GREEN FLUORESCENT PROTEIN; NANOCARRIER; NUCLEIC ACID; PLASMID DNA; SOLID LIPID NANOPARTICLE; TRISTEARIN; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; ELECTROPHORESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STATIC ELECTRICITY; ZETA POTENTIAL;

ANIMALS; DNA; GENE TRANSFER TECHNIQUES; HEP G2 CELLS; HUMANS; LIPIDS; MATERIALS TESTING; NANOPARTICLES; PLASMIDS; SALMON; TRANSFECTION;

EID: 84889564230     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2013.10.001     Document Type: Article

References (71)

1. Deng W., et al. Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the lung for pulmonary hypertension. Methods Mol. Biol. 2010, 610:309-321.
2. Edelstein M.L., et al. Gene therapy clinical trials worldwide to 2007: an update. J. Gene Med. 2007, 9:833-842.
3. Brenner M.K., Okur F.V. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am. Soc. Hematol. Educ. Program 2009, 675-681.
4. Assi H., et al. Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci. Lett. 2012, 527:71-77.
5. Keeler A.M., Flotte T.R., et al. Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome. Hum. Gene Ther. 2012, 23:548-556.
6. Spitali P., Aartsma-Rus A., et al. Splice modulating therapies for human disease. Cell 2012, 148:1085-1088.
7. Pinotti M., et al. RNA-based therapeutic approaches for coagulation factor deficiencies. J. Thromb. Haemost. 2011, 9:2143-2152.
8. Martone J., et al. U1 snRNA as an effective vector for stable expression of antisense molecules and for the inhibition of the splicing reaction. Methods Mol. Biol. 2012, 867:239-257.
9. Patil S.D., et al. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 2005, 7:E61-E77.
10. Merdan T., et al. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 2002, 54:715-758.
11. Pedroso de Lima M.C., et al. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv. Drug Deliv. Rev. 2001, 47:277-294.
12. Chirmule N., et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999, 6:1574-1583.
13. Manno C.S., et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 2006, 12:342-347.
14. Muller R.H., et al. Solid lipid nanoparticles (SLN) for controlled delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
15. Westesen K., Siekmann B. Biodegradable colloidal drug carrier systems based on solid lipids. Microencapsulation 1996, 213-258. Marcel Dekker, New York. S. Benita (Ed.).
16. Westesen K., et al. Physicochemical characterisation of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control. Release 1997, 48:223-230.
17. Yaghmur A., Glatter O. Characterisation and potential applications of nanostructured aqueous dispersions. Adv. Colloid Interface Sci. 2009, 148:333-342.
18. Siekmann B., et al. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride/water phases. Int. J. Pharm. 2002, 244:33-43.
19. de Campo L., et al. Reversible phase transitions in emulsified nanostructured lipid systems. Langmuir 2004, 20:5254-5261.
20. Gustafsson J., et al. Submicron particles of reversed lipid phases in water stabilised by a nonionic amphiphilic polymer. Langmuir 1997, 13:6964-6971.
21. Larsson K. Aqueous dispersions of cubic lipid/water phases. Curr. Opin. Colloid Interface Sci. 2000, 5:64-69.
22. Boyd B.J., et al. Hexosomes formed from glycerate surfactants-Formulation as a colloidal carrier for irinotecan. Int. J. Pharm. 2006, 318:154-162.
23. Esposito E., et al. Lipid based supramolecular systems for topical application: a preformulatory study. AAPS PharmSci 2003, 4. article 30.
24. Kim J.S., et al. Drug formulations that form a dispersed cubic phase when mixed with water. Proc. Int. Symp. Control. Release Bioact. Mater. 2000, 27:1118-1119.
25. Spicer P.T., Hayden K.L. Novel process for producing cubic liquid crystalline nanoparticles (cubosomes). Langmuir 2001, 17:5748-5756.
26. Worle G., et al. Influence of composition and preparation parameters on the properties of aqueous monoolein dispersions. Int. J. Pharm. 2007, 329:150-157.
27. Nakano M., et al. Small angle X-ray scattering and 13C NMR investigation on the internal structure of cubosome. Langmuir 2001, 17:3917-3922.
28. Almgrem M., et al. Cryo transmission electron microscopy of liposomes and related structures. Colloids Surf. A 2000, 174:3-21.
29. Sagalowicz L., et al. Investigating reversed liquid crystalline mesophases. Curr. Opin. Colloid Interface Sci. 2006, 11:224-229.
30. Fernandez Alanis E., et al. An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects. Hum. Mol. Genet. 2012, 21:2389-2398.
31. Rizzotto L., et al. Intracellular evaluation of ER targeting elucidates a mild form of inherited coagulation deficiency. Mol. Med. 2006, 12:137-142.
32. Esposito E., et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm. Res. 2005, 22:2163-2173.
33. Esposito E., et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm. Res. 2008, 25:1521-1530.
34. Hiramatsu N., et al. HCV cDNA transfection to HepG2 cells. J. Viral Hepat. 1997, 4:61-67.
35. van de Loosdrecht A.A., et al. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. Immunol. Methods 1994, 174:311-320.
36. Cortesi R., et al. Long-chain cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as new components of potential non-viral vectors. Int. J. Pharm. 2012, 431:176-182.
37. Worle G., et al. Transformation of vesicular into cubic nanoparticles by autoclaving of aqueous monoolein/poloxamer dispersions. Eur. J. Pharm. Sci. 2006, 27:44-53.
38. Lindstrom M., et al. Aqueous lipid phases of relevance to intestinal fat digestion and absorption. Lipids 1981, 16:749-754.
39. Schubert M.A., Muller-Goymann C.C. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm. 2005, 61:77-86.
40. Muller R.H., et al. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int. J. Pharm. 1996, 138:85-94.
41. Heydenreich A.V., et al. Preparation and purification of cationic solid lipid nanospheres - effects on particle size, physical stability and cell toxicity. Int. J. Pharm. 2003, 254:83-87.
42. Tabatt K., et al. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticles-mediated gene transfer. Eur. J. Pharm. Biopharm. 2004, 57:155-162.
43. Sternberg B., et al. New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. FEBS Lett. 1994, 356:361-366.
44. Faneca H., et al. Evaluation of lipid-based reagents to mediate intracellular gene delivery. Biochim. Biophys. Acta 2002, 1567:23-33.
45. Liu F., et al. New cationic lipid formulations for gene transfer. Pharm. Res. 1996, 13:1856-1860.
46. Kim T.W., et al. The role of non-ionic surfactants on cationic lipid mediated gene transfer. J. Control. Release 2002, 82:455-465.
47. Olbrich C., et al. Cationic solidlipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control. Release 2001, 77:345-355.
48. Chen J., et al. Preparation, characterisation and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery systems. J. Biotechnol. 2007, 130:107-113.
49. del Pozo-Rodríguez A., et al. Solid lipid nanoparticles: Formulation factors affecting cell transfection capacity. Int. J. Pharm. 2007, 339:261-268.
50. del Pozo-Rodríguez A., et al. Proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J. Control. Release 2009, 133:52-59.
51. Choi S.H., et al. Novel cationic solid lipid nanoparticles enhanced p53 gene transfer to lung cancer cells. Eur. J. Pharm. Biopharm. 2008, 68:545-554.
52. del Pozo-Rodríguez A., et al. Solid lipid nanoparticles as potential tools for gene therapy: in vivo protein expression after intravenous administration. Int. J. Pharm. 2010, 385:157-162.
53. Ogris M., Wagner E. Tumor-targeted gene transfer with DNA polyplexes. Somat Cell Mol Genet. 2002, 27:85-95.
54. Delgado D., et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterisation and in vivo transfection after intravenous administration to mice. Int. J. Pharm. 2012, 425:35-43.
55. Masuda T., et al. Evaluation of nuclear transfer and transcription of plasmid DNA condensed with protamine by microinjection: the use of a nuclear transfer score. FEBS Lett. 2005, 579:2143-2148.
56. del Pozo-Rodríguez A., et al. Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides. Recent Patents Drug Deliv. Formul. 2011, 5:214-226.
57. Sakurai F., et al. Effect of NA/Liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. J. Control. Release 2000, 66:255-269.
58. Moore N.M., et al. Characterisation of a multifunctional PEG-based gene delivery system containing nuclear localization signals and endosomal escape peptide. Acta Biomater. 2009, 5:854-864.
59. Rejman J., et al. Role of clathrin- and caveolae mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol. Ther. 2005, 12:468-474.
60. Noguchi A., et al. Cationic cholesterol promotes gene transfection using the nuclear localization signal in Protamine. Pharm. Res. 2002, 19:933-938.
61. Lv H., et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 2006, 114:100-109.
62. Wissing, et al. Solid lipid nano-particles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56:1257-1272.
63. Yang, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 1999, 59:299-307.
64. Mehnert, Mader Solid lipid nanoparticles, production, characterisation and applications. Adv. Drug Deliv. Rev. 2001, 47:165-196.
65. Jeong Park. Poly(l-lysine)-g-poly(d,l-lactic-co-glycolic acid) micelles for low cytotoxic biodegradable gene delivery carriers. J. Control. Release 2002, 82:159-166.
66. Chollet, et al. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J. Gene Med. 2002, 4:84-91.
67. Kaur, et al. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 2008, 127:97-109.
68. Müller J. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71:161-172.
69. Tseng, et al. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 2009, 61:721-731.
70. Vighi, et al. pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int. J. Pharm. 2010, 389:254-261.
71. Vighi, et al. Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterisation and ability to bind pEGFP-plasmid.Eur. J. Pharm. Biopharm. 2007, 67:320-328.